Drug Discovery

#AI #Biotechnology #Chemistry #Digital #Drug discovery #Life sciences

Digital Science launches research platform 

Digital Science has launched a new version of its Dimensions platform – Dimensions Life Sciences & Chemistry – focused on life sciences and chemistry research activities.   Dimensions L&C analyses more than 120 million scientific publications, millions of patents, grants and clinical trial documents. It applies semantic text analysis tools… Read More

#Business & Investment

#Biologics / Biotechnology #Collaboration #Drug development

Collaboration aims to accelerate cyro-EM research 

Amgen and the University of Southern California (USC) are working together to provide researchers access to two cryo-transmission electron microscopes (cryo-EMs) – the Thermo Scientific Krios and Glacios.  Access to the two instruments in one shared location allows researchers from both institutions to combine resources to bring more speed and… Read More

#News

#Automation / robotics #Drug discovery #ELRIG #Events #Screening #SLAS

ELRIG’s Drug Discovery 2021 to host SLAS’s Innovation AveNEW 

The European Laboratory Research & Innovation Group (ELRIG) UK has announced programme details for Drug Discovery 2021, which will take place at the Exhibition Centre ACC in Liverpool, UK, from October 19–20. The Society for Laboratory Automation and Screening (SLAS) will host its Innovation AveNEW to showcase emerging innovations and companies. … Read More

#News #Trending News

#Clinical trials #Drug development #Drug discovery

Lung fibrosis drug may help heart failure patients 

An early phase trial of pirfenidone, a drug currently used to treat lung fibrosis, has shown it may also help patients who suffer from a common form of heart failure in a study funded by the National Institute for Health Research, published in Nature Medicine.  Trialed in… Read More

#News

#CRISPR #Drug discovery #Funding #Gene editing #HIV #Research

NIH invests $53 million in HIV cure research  

The National Institutes of Health (NIH) has awarded approximately $53 million in annual funding over the next five years to ten research organisations in a continued effort to find a cure for HIV.   The new awards for the Martin Delaney Collaboratories for HIV Cure Research programme expand the initiative’s 2016 renewal from six… Read More

#Business & Investment #News

#Drug development #Informatics #Research

Dotmatics to deliver the foundation for Croda’s R&D digital programme 

Dotmatics, a scientific informatics software and services company, has been selected by Croda International to implement its research and development (R&D) digital program. This project will reportedly deepen Croda’s ability to innovate collaboratively, both internally and externally, delivering enhanced data science capability across the company’s global R&D… Read More

#News

#Biomanufacturing #Biosciences #Biotherapeutics #Drug development #Therapeutics

Partnership to develop and manufacture biosimilars

Abzena and BioXpress Therapeutics have partnered to support biosimilar development for third party customers, creating an integrated solution between two service providers with expertise in biosimilar development and GMP manufacture. The partnership will ensure biosimilar drug developers benefit from an integrated approach to biosimilars spanning the range from design consultancy,… Read More

#News

#Drug development #Funding #Mental health

Funding completed to develop psychedelic medicine breakthroughs

Beckley Psytech has completed Series B financing, raising $80 million from venture capital (VC) investors to fund its research programmes. The financing was initially set at $50 million and was upsized to $80 million due to interest from investors in broadening and accelerating the clinical development of Beckley Psytech’s research… Read More

#News

#Biomanufacturing #Corning Life Sciences #Drug discovery #Immunology / Virology & Vaccines #Life sciences #SARS-CoV-2

Optimising vaccine production through customisation

Listen to this article on the DDW Podcast: An expert’s view by John Yoshi Shyu, Ph.D. Corning Life Sciences. Most vaccines are manufactured using technology devised fifty or more years ago, in manufacturing plants that are sometimes even older. The vaccine production process is continually refreshed by new tools… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News

#Alzheimer's #Drug development #Funding #Research

NIH awards $15 million for Alzheimer’s research

The National Institute of Aging (NIA), part of the National Institutes of Health, has awarded Wake Forest School of Medicine $15.2 million over five years in support of its research centre for Alzheimer’s disease. Established in 2016 with a multimillion-dollar NIA grant, the Alzheimer’s Disease Research Center (ADRC) at Wake… Read More

#News #Trending News

#Clinical trials #Drug development #Drug discovery #Infectious diseases #Research

This week in drug discovery (9-13 August)

News round-up by DDW’s Megan Thomas for 9-13 August This week, DDW’s Megan Thomas has rounded up five stories which report positive data and findings from around the globe in the drug discovery sector. Preclinical data on oral polymer-based duodenal exclusion therapy Glyscend has presented data during the American… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #Assays #Covid-19 #Drug development

Human studies begin on AI Covid-19 treatment with up to 97% effectiveness

Skymount Medical and Louisiana State University (LSU) have commenced human studies on a unique combination of therapies for Covid-19 patients, known as SM-19. In vitro and in vivo assays conducted by the IIT Research Institute (IITRI) in Chicago showed significant efficacy in reducing viral load of the SARS-Cov-2 virus. The… Read More

#News #Trending News

#Biotechnology #Drug discovery #Exscientia #Technology

Exscientia builds automated laboratories to expand pipeline

Exscientia has announced the opening of a 21,000 square foot expansion of its facilities at Oxford Science Park, UK, increasing capacity for its technology teams as well as significantly expanding its laboratory-based experimental capabilities in structural biology, biophysics and high-content pharmacology. In parallel, Exscientia is building a new 26,000 square… Read More

#News #Trending News

#AI / data analytics / healthtech / informatics #Cancer research #Drug discovery #Exscientia #Immuno-oncology

Spotlight: AI in drug discovery first

Earlier this year, Exscientia announced what was said to be the first AI-designed immuno-oncology drug to enter clinical trials. Lu Rahman talks to CEO Andrew Hopkins about the company’s work and use of AI in drug discovery. LR:  How AI has been used in this process and what benefits has… Read More

#Cancer Research #Editor's Choice #Exclusive Content #News

#Clinical trials #Drug development #Lipidomics

Phase II clinical trial of ASC40 approved for acne treatment

Ascletis Pharma has announced that China National Medical Products Administration (NMPA) has approved the Phase II clinical trial application of ASC40 for the treatment of patients with moderate to severe acne. The Phase II trial is a randomised, double-blind, placebo-controlled, multicentre clinical trial to be conducted in China to evaluate… Read More

#News #Trending News